Intercell starts an additional efficacy trial for its patch-based investigational Travelers’ Diarrhea Vaccine System in Asia(05 Jan 2010) Phase II pilot efficacy trial - placebo controlled field study to evaluate efficacy and enterotoxigenic E. coli (ETEC) incidence of vaccinated European travelers to India Intercell AG announced the start of a Phase II study in India as part of its clinical development program for the investigational Travelers’ Diarrhea (TD) Vaccine system. This placebo controlled field study with vaccinated travelers from the EU to ...
Intercell provides update on ongoing Phase II vaccine studies(17 Dec 2009) Pseudomonas vaccine: Study in intensive care patients to investigate immunogenicity and safety of a Pseudomonas aeruginosa vaccine and to assess Pseudomonas infection rates Intercell AG announced that interim data from a Phase II clinical trial investigating the compan's vaccine candidate for the prevention of infections with the bacterium Pseudomonas aeruginosa are available. Intercell's vaccine is a recombinant ...
Intercell Announces First Subject Enrolled in a Phase II Trial for the further development of its Vaccine Enhancement Patch(02 Jun 2009) Phase II clinical trial investigating the effectiveness of Intercell’s Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine Intercell AG announced that it has advanced its efforts to develop its VE Patch to improve prevention of H5N1 pandemic influenza with the start of a Phase II clinical trial. The randomized and blinded study aims to determine the optimal dosage of ...
Intercell Executes Multi-Year Contract for Supply of IXIARO to the United States Military(15 May 2009) First sales of IXIARO under this military contract expected soon Intercell AG announced that the Company has successfully entered into a multi-year contract with the Defense Logistics Agency (DLA), Defense Supply Center of the U.S. Department of Defense to supply IXIARO, a vaccine against Japanese Encephalitis ...
Intercell starts a Phase I clinical trial for a new Streptococcus pneumoniae vaccine(08 Apr 2009) Study aims to obtain safety and immunogenicity data of this new vaccine candidate Intercell AG announced that a Phase I clinical trial with the compan's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.Intercell's vaccine candidate is a recombinant subunit vaccine consisting ...
Top
